Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.27 USD | -0.47% | -2.88% | -11.34% |
May. 10 | Exelixis Files Patent Complaint Against Cipla's Cancer Treatment | DJ |
May. 01 | RBC Trims Exelixis' Price Target to $27 From $28, Outperform Rating Kept | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.34% | 6.22B | |
+5.66% | 109B | |
+11.23% | 105B | |
-0.38% | 22.25B | |
-12.15% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-10.09% | 16.85B | |
+3.33% | 13.76B | |
+36.58% | 12.46B |
- Stock Market
- Equities
- EXEL Stock
- News Exelixis, Inc.
- Insider Sell: Exelixis